Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.55 EUR | +1.49% | +6.52% | +92.56% |
Apr. 26 | Guerbet: quarterly sales up by nearly 8 | CF |
Apr. 25 | Guerbet SA Provides Earnings Guidance for the Year 2024 | CI |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.91 for the current period. Therefore, the company is undervalued.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+91.03% | 499M | B+ | ||
-3.22% | 15.01B | - | ||
-36.36% | 2.91B | C- | ||
-12.35% | 2.46B | - | ||
-12.00% | 1.46B | - | - | |
-.--% | 1.12B | - | - | |
+40.97% | 519M | - | ||
+12.77% | 243M | C | ||
+1.30% | 183M | - | ||
-.--% | 168M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GBT Stock
- Ratings Guerbet